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pre-existing ones. Many developmental and pathological 
processes require angiogenesis[1]. As proposed by Folkman 
in 1971, angiogenesis is required for tumor growth[2]. 
Angiogenesis consists of  several steps: endothelial cell (EC) 
proliferation, migration, basement membrane degradation, 
and new lumen organization[3]. This multi-step process 
is determined by a net balance between pro- and anti-
angiogenesis regulators in the circulation blood, which are 
released from activated ECs, monocytes, smooth muscle 
cells and platelets[3].
The g rowth of  tumor depends on new blood 
vessel growth and involves three steps: angiogenesis, 
va scu log enes i s and in tus susce p t ion [4] . Wi thout 
angiogenesis, a solid tumor rarely grows larger than 2 
to 3 mm[5]. As shown in Figure 1, ECs and tumor cells 
release angiogenesis regulators like vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor 
(bFGF) and transforming growth factor (TGF) to mediate 
angiogenesis. The result is the development of  invasive 
tumor. In addition to the presence of  angiogenesis factors, 
activation of  oncogene and loss of  tumor suppressor 
gene are also essential for an angiogenesis phenotype that 
supports tumorigenicity[6]. As a result, anti-angiogenesis 
has been regarded as a target for cancer therapy. 
There are already several extensive reviews on 
the development of  anti-angiogenesis cancer gene 
therapy[3,7-10]. In the 2001 review, Liau et al[7] compared and 
contrasted the gene approach and recombinant protein 
approach. In the editorial written by Lau and Bicknel[9], 
the authors compared the delivery of  the genes of  anti-
angiogenic factors with that of  the therapeutic proteins. 
They suggested that the delivery of  genes can allow a 
high local expression of  the protein at the sites of  active 
tumor growth[9]. El-Aneed pointed out in his review, 
which summarizes the strategies in cancer gene therapy, 
that the ease of  accessing ECs of  the blood vessels is 
one of  the main advantages of  gene delivery approach[10]. 
Figure 2 shows that the delivery of  the anti-angiogenesis 
gene into tumor cells or ECs can inhibit tube formation, 
EC migration and proliferation. This can result in tumor 
necrosis. In this review, updated information on the 
development of  cancer anti-angiogenesis gene therapy is 
discussed.
ANTI-ANGIOGENESIS CANCER GENE 
THERPAY STRATEGIES
RNA interference 
RNA interference (RNAi) is the sequence-specific gene 
 REVIEW
Cancer gene therapy targeting angiogenesis: An updated 
review
www.wjgnet.com
Ching-Chiu Liu, Zan Shen, Marie CM Lin, Institute of Molecular 
Technology for Drug Discovery and Synthesis, Department of 
Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, 
China
Hsiang-Fu Kung, Centre for Emerging Infectious Diseases, The 
Chinese University of Hong Kong, Shatin, Hong Kong, China
Supported by grant from the Innovation and Technology 
Commission of the Hong Kong SAR to HFK and MCL 
(ITS/084/03), AoE scheme of UGC, and from Li Ka Shing 
Institute of Health Sciences to HFK
Correspondence to: Dr. Marie CM Lin, Institute of Molecular 
Technology for Drug Discovery and Synthesis, Department of 
Chemistry, Rm 8N11, Kadoorie Biological Science Building, The 
University of Hong Kong, Pokfulam Road, Hong Kong, 
China. mcllin@hkusua.hku.hk
Telephone: +852-22990776  Fax: +852-28171006
Received: 2006-03-24           Accepted: 2006-09-20
Abstract
Since the relationship between angiogenesis and 
tumor growth was established by Folkman in 1971, 
scientists have made efforts exploring the possibilities 
in treating cancer by targeting angiogenesis. Inhibition 
of angiogenesis growth factors and administration 
of angiogenesis inhibitors are the basics of anti-
angiogenesis therapy. Transfer of anti-angiogenesis 
genes has received attention recently not only because 
of the advancement of recombinant vectors, but also 
because of the localized and sustained expression of 
therapeutic gene product inside the tumor after gene 
transfer. This review provides the up-to-date information 
about the strategies and the vectors studied in the field 
of anti-angiogenesis cancer gene therapy.
© 2006 The WJG Press. All rights reserved.
Key words: Anti-angiogenesis; Tumor growth; Cancer 
gene therapy
Liu CC, Shen Z, Kung HF, Lin MCM. Cancer gene therapy 
targeting angiogenesis: An updated review. World J 
Gastroenterol 2006; 12(43): 6941-6948
 http://www.wjgnet.com/1007-9327/12/6941.asp
INTRODUCTION
Angiogenesis is the formation of  new blood vessels from 
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silencing induced by double-stranded RNA. Introduction 
of  21-23 small interfering RNAs (siRNAs) of  the 
nucleotide can knock-out the expression of  a particular 
gene[11]. A recent review written by Izquierdo[12] pointed 
out that siRNA against expression of  vascular growth 
factor receptor (VGFR) can reduce tumor volume by 
blocking angiogenesis. Kwon and co-workers[13] described 
a method that can suppress the expression of  VGFR-A 
at both transcriptional and post-transcriptional levels by 
a combination of  zinc finger protein and siRNA. Gondi 
and co-workers[14] have demonstrated the potential 
application of  RNAi in gene cancer therapy by inhibiting 
angiogenesis in both in vivo and in vitro human glioma cell 
models. Furthermore, it is possible to include more than 
one antiangiogenesis siRNA into a single retroviral vector 
because of  the small size of  siRNA, which could inhibit 
multiple pathways[12]. 
Antisense oligodeoxynucleotide 
Antisense oligodeoxynucleotide (ODN) is a synthetic 
molecule that blocks mRNA translation. The blockade of  
translation of  mRNA of  pro-angiogenesis factor genes 
can result in inhibition of  tumor growth. Recently, ODN 
blocking of  the expression of  VEGF has been shown to 
be a promising cancer gene therapy. For example, Wang 
et al[15] have successfully reduced VEGF protein expression 
by 45% in human osteosarcoma cell line by transducing 
a eukaryotic expression plasmid containing antisense 
VEGF. Lipiodol is an effective treatment for unresectable 
liver cancer through transcatheter arterial embolization 
of  the hepatic artery[16]. When VEGF antisense ODN is 
mixed with lipiodol, this combinational approach is better 
in inhibiting liver cancer growth, VEGF expression and 
microvessel density[16].
Expressing the genes of angiogenesis inhibitors
Table 1 summarizes the genes of  candidate angiogenesis 
inhibitors that have been studied recently. In the review 
published in the Journal of  Translational Medicine[3], the 
authors made a thorough account of  several candidates. 
To avoid overlapping of  information, we only discuss 
those candidates that are not covered or recently have 
demonstrated significant advancement.
Maspin: The Maspin gene is a tumor suppressor gene 
which is under transcriptional control by p35 and DNA 
methyltransferase inhibitors. Its gene expression level 
decreases with malignancy and is lost in metastatic 
cells[17,18]. Transfection of  maspin gene to nude mice 
could reduce the ability of  cells to induce tumors and 
metastasis[19]. Recently, Watanabe et al[18] have shown that 
adeno-associated virus 2-mediated expression of  human 
maspin can efficiently suppress tumor growth by inhibition 
of  angiogenesis in prostate cancer. 
Human ribonuclease inhibitor: Human ribonuclease 
inhibitor (hRI) is an acidic protein with a molecular weight 
of  50 kDa. It can inhibit the activity of  pancreatic RNase 
(RNase A)[20]. It is proposed that hRI inhibits angiogenesis 
by forming a tight complex with its counterpart angiogenin 
(Ang) which is an angiogenesis factor[21]. Fu et al [20] 
demonstrated that hematopoietic cells carrying the ri gene 
can effectively inhibit tumor growth (by 47%) and reduce 
tumor microvessel density in mice. They concluded that 
hRI has the potential utility as a novel antiangiogenesis 
agent[20].
Survivin: Survivin has been identified as an anti-apoptosis 
gene over-expressed in cancer and lymphoma[22]. It has 
been shown that survivin is minimally expressed in 
endothelium of  non-proliferating capillaries of  normal 
skin, whereas it becomes massively up-regulated in newly 
formed blood vessels of  granulation tissue in vivo. As a 
result, manipulation of  survivin expression and function in 
endothelium may influence tumor angiogenesis[23]. Recently, 
a DNA vaccine targeting survivin and an adeno-associated 
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Figure 1  Release of angiogenesis factors mediates the development of invasive 
tumor.
Figure 2  Therapeutic actions of anti-angiogenesis gene therapy.
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viral vector carrying survivin Cys84Ala mutant have been 
employed to demonstrate the anti-angiogenesis effect on 
lung tumor and colon cancer cells respectively[24,25]. 
Soluble FMS-like tyrosine kinase receptor 1: Soluble 
FMS-like tyrosine kinase receptor 1 (sFlt-1) has been 
identified as a receptor of  vascular endothelial growth 
factor (VEGF)[26]. It functions by sequestering VEGF 
and forming inactive heterodimers with other membrane-
spanning VEGF receptors both in in vitro and in vivo[26]. 
Intramuscular injection of  recombinant adeno-associated 
virus (rAAV) vectors carrying the sFlt-1 gene into nude 
mice can protect against the human ovarian cancer cell line 
with increased disease-free survival[27].
Interleukin-12: In 2004 and 2005, Heinzerling et al[28] and 
Imagawa et al[29] showed that direct intratumoral injection 
of  interleukin-12 (IL-12) gene produces a reduction 
in vessel density or angiogenesis in a murine head and 
neck cancer model and in patients with metastatic 
melanoma[28,29]. It is worth noting that a few cytokines, like 
IL-12, have recently been reported to participate in the 
regulation of  the angiogenic switch[30]. These cytokines are 
related to inflammation. Whether there are relationships 
between angiogenesis and inflammation may be an 
interesting topic among scientists in the future. 
Pigment epithelium-derived factor: Pigment epithelium-
derived factor (PEDF) is a neurotrophic protein and 
belongs to the serine protease inhibitor (serpin) family[31,32]. 
It is believed to be a potent inhibitor of  angiogenesis[33]. 
A full-length human PEDF expression vector has been 
used to transfect the glioma cell line U251, resulting in up-
regulation and down-regulation of  angiogenesis inhibitors 
and activators[34]. 
Tissue inhibitors of  metalloproteinase: In 2004, 
adeno-associated virus-mediated gene transfer of  tissue 
inhibitor of  metalloproteinase (TIMP) to animal’s tumor 
also showed that it can inhibit vascular tumor growth and 
angiogenesis[35].
Angiostatin: Angiostatin is a 38 kD kringle domain of  
plasminogen and is the most potent and well characterized 
body’s angiogenesis inhibitor[3]. Recently, the effectiveness 
of  co-administration of  the mouse angiostatin kringle and 
the endostatin genes using cationic liposome has been 
investigated in vitro and in vivo by Kim et al[36].
Melanoma differentiation-associated-7 gene or 
interleukin-24: Melanoma differentiation-associated-7 
(mda-7) gene is a novel melanoma differentiation-
associated gene that modulates human melanoma 
differentiation, growth and progression. It was identified 
by subtractive hybridization in human melanoma cells by 
Jiang et al[37]. It has been demonstrated that the mda-7 gene 
functions as a multi-modality anti-cancer agent, possessing 
both pro-apoptotic and anti-angiogenic properties, and the 
adenovirus-mediated over-expression of  mda-7 gene has 
the potential therapeutic effects in human lung cancer[38]. 
More recently, Nishikawa et al[39] performed a combination 
therapy on non-small-cell lung cancer (NSCLC) cell lines 
and showed that the combination of  mda-7 gene therapy 
and radiotherapy may be a feasible and effective strategy 
for treatment of  NSCLC.
Fragments of  hepatocyte growth factor: NK4 is the 
N-terminal hairpin domain and subsequent four-kringle 
domains of  hepatocyte growth factor (HGF). It was 
reported that HGF possesses anti-angiogenesis property[40]. 
A latest trial has been done using hydrodynamics-based 
gene delivery of  naked NK4 plasmid into colon cancer 
cells in mice. HGF can efficiently express NK4, inhibit 
liver metastasis and subsequent invasive growth of  colon 
cancer and prolong survival of  mice[41]. In addition to 
NK4, recombinant kringle 1 domain of  HGF (HGFK1) 
has been shown to inhibit bovine aortic endothelial cell 
proliferation stimulated by basic fibroblast growth factor 
(bFGF) in a dose-dependent manner[42]. These studies 
present the potency of  the fragments of  HGF in inhibiting 
angiogenesis. 
NC1 domains of  collagen: Endostatin (from collagen 
XⅧ), restin (from collagen XV), arrestin (α 1 chain of  
collagen Ⅳ) and canstatin (α 2 chain of  collagen Ⅳ) are 
all NC1 domains as reviewed by Tandle et al[3]. Recently it 
has been shown that vastatin, the NCI domain of  collagen 
Ⅷ (α 1) possesses anti-angiogenesis ability in bovine 
aortic endothelial cells[43]. This provides another promising 
candidate for caner anti-angiogenesis gene therapy. 
GENE DELIVERY SYSTEMS
The viral vectors used for tumor vascular targeting therapy 
are summarized in a recent review[44]. Tandle et al[3] have 
also discussed some non-viral gene delivery vectors. Again, 
we will focus on those newly studied viral vectors showing 
advancement. Table 2 summarizes the vectors that are 
Table 1  Genes of canadidate angiogenesis inhibitors
1Candidates that have been covered in Tandle et al[3].
Candidate Reference(s)
16 kD prolactin fragment1 3
Angiostatin1 3, 36
Arresten1 3
Canstatin1 3
Endostatin1 3
Endothelial-monocyte activating polypeptide-Ⅱ (EMAP-Ⅱ)1 3
Fragments of hepatocyte growth factor (HGF)
   NK4
   HGFK1
40, 41
42
Human rubonuclease inhibitor (hRI) 20, 21
Interferon-inducible protein-10 (IP-10)1 3
Interferons1 3
Interleukin-12 (IL-12)1 28, 29
Interleukin-18 (IL-18)1 3
Interleukin-24 (IL-24) 37, 38, 39
Maspin 17, 18, 19
p531 3
Pigment epithelium-derived factor (PEDF) 31, 32, 33, 34
Platelet factor-41 3
Restin1 3
Soluble FMS-like tyrosine kinase receptor 1 (sFlt-1) 26, 27
Survivin 22, 23, 24, 25
Thrombospondin-1 (THBS1)1 3
Tissue inhibitors of metalloproteinases (TIMPs)1 3, 35
Tumor necrosis factor alpha (TNF-α)1 3
Tumstatin1 3
Vastatin1 43
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recently used in cancer antiangiogenesis gene therapy. 
Nanoparticles: Polymeric drug carriers are used to deliver 
low molecular mass drugs, oligonucleotides and peptides, 
which has attracted attention in recent years[3]. Due to 
their small sizes, nanoparticles penetrate into even small 
capillaries and are taken up by cells that can deliver targeted 
drugs to cells or tissues[3]. In 2005, Schiffelers et al[45] 
constructed self-assembling nanoparticles with siRNA as a 
means to target tumor neovasculature expressing integrins 
and to deliver siRNA which inhibits VEGF-R2 expression 
and thereby tumor angiogenesis. They pointed out that this 
mode of  delivery overcomes the pharmacological hurdles 
of  local administration of  aqueous siRNA for cancer 
therapy.
Cationic l iposome: The advantages of  us ing a 
cationic liposome as a vehicle for drug delivery are the 
enhancement of  delivery and expression of  the transfected 
gene. The positive charge significantly increases the uptake 
of  liposome by the endothelial cells of  blood vessels 
in tumor tissues, which has made the cationic liposome 
useful for delivering tumor targeted drugs[46]. A recent 
successful case of  angiogenesis inhibition using angiostatin 
and endostatin genes delivered by a cationic liposome has 
been reported. In addition, modified liposome targeting 
membrane type-1 matrix metalloproteinase (MT1-
MMP) molecules expressed specifically on angiogenesis 
endothelium and tumor cells, enhances its binding to 
and accumulates ECs in tumor compared to unmodified 
liposome[47]. 
Low voltage electroporation: Electroporation is the 
formation of  pores on the cell surface induced by electric 
pulse. Direct delivery of  plasmid DNA into cells relies 
on electroporation. In vivo electroporation is a novel non-
viral means of  gene transfer and offers several advantages 
over viral means such as none of  immunogenicity, ease 
of  handling and high gene transfer efficiency[48]. Uesato 
and co-workers[49] have successfully demonstrated the anti-
tumor effect of  antiangiogenesis genes, mouse angiostatin 
and mouse endostatin, delivered to tumors by low-voltage 
electroporation in 26 models of  mouse colon. They 
have also reported a decrease in microvessel density of  
tumors[49]. 
Semliki forest virus: A new expression vector system 
derived from semiliki forest virus (SFV) was introduced 
in 1994[50]. This system has been utilized in delivering 
glycoproteins in a recombinant vaccine study[51]. The 
vector has also been shown to be a candidate medium for 
human cancer gene therapy[52]. More recently, SFV vector 
carrying murine IL-12 gene demonstrated by Doppler 
ultrasonography, could cause B16 tumor regression 
through anti-angiogenesis[53]. After this, two IL-12 gene 
subunits cloned from mouse splenocytes and inserted 
into an enhanced SFV vector (pSFV10-E) could show 
complete tumor regression in mice[54].
Replication-competent retroviruses: Retroviruses are 
a class of  virus which has a genome of  a single stranded 
RNA molecule. Vectors derived from murine leukemia 
virus, a simple retrovirus, have been used in in vivo gene 
transfer in gene therapy. However, the limited efficiency of  
replication-defective retrovirus vector is a major obstacle 
in cancer gene therapy[55]. Logg’s group in Los Angeles 
thus developed a replication-competent retrovirus (RCR) 
vector derived from murine leukemia virus[55]. This vector 
is able to replicate and transmit a transgene both in culture 
and in a solid tumor model in vivo. By taking advantages 
from RCR vectors, Sun et al[56] transduced RCR vectors 
carrying the human interferon-inducible protein-10 (IP-10) 
gene to tumor cells in vivo and in vitro, showing sustained 
production of  IP-10 in culture and reduced angiogenesis 
in mice. 
Recombinant adenovirus: Adenovirus has a double 
stranded DNA genome. Recombinant adenovirus (rAdv) 
vectors containing exogenous genes for in vivo transfer 
derived from adenovirus type 5 are made replication 
deficient by deletion of  the E1 region[57]. rAdv is currently 
the most widely used gene delivery vector because it 
Table 2  Gene delivery vectors
Vector Brief description Reference (s)
Cationic liposomes Spherical vesicle made of positively charged lipids, efficient uptake of DNA by the cell 46, 47
Low Voltage Electroporation Entry of DNA into the cell whose membrane is permeabilized by electric field, efficient gene
transfer is ensured
48, 49
Nanoparticles Submicron-sized particle with the therapeutic agent situated within the matrix or on the surface 3, 45
Measles virus Contains negative strand RNA molecule, can enter tumor cells without the defensive 
responses of the tumor
44
Herpes simplex virus Dobule stranded DNA virus, wide host range, large transgene capacity, long-lasting effect 3, 44
Lentivirus Derived from HIV, can achieve stable integration of the gene in non-dividing cells 3, 44
Retrovirus Based on murine leukemia virus, foreign cDNA can be incorporated into host cell 
genome with high efficiency
3, 44
Replication-competent 
Retrovirus (RCR)
Modified retroviral vector that can replicate in solid tumor model so the transfer efficiency
is enhanced
55, 56
Semliki Forest Virus (SFV) One type of alphavirus, modification of its RNA genome yield a new expression vector
that transfers transgene into tumor
50, 51, 52, 53, 54
Recombinant adenovirus
(rAdv)
Double stranded DNA virus, can be produced in high titres and deliver transgene efficiently
Special engineered adenovirus: oncolytic and gutless
3, 57, 58, 59, 60, 61, 
62, 63, 64
Recombinant adeno-associated 
virus (rAAV)
Possess the advantages of rAdv and retrovirus, low level of immune response 3, 25, 65, 66, 67, 68
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enjoys several advantages like high delivery efficiency 
into both dividing and non-dividing cells, large ability to 
package foreign genes, easy to grow to high titers and to 
be purified, non-oncogenic and high expression of  the 
transgenes[58]. In recent years, phaseⅠtrials have been 
undertaken using adenoviral p53 (Adp53) for patients 
with ovarian cancer[59]. In China, phaseⅠand Ⅱ trials 
using recombinant Adp53 to treat laryngeal cancer (phase
Ⅰ), head and neck squamous cell carcinoma (phase Ⅱ) 
and nasopharyngeal carcinoma (phase Ⅱ) have been 
undertaken extensively[60-62].
Oncolytic adenovirus is a special ly engineered 
adenovirus which exhibits lytic property of  virus 
replication[63]. This adenoviral system not only offers the 
advantage of  high gene delivery efficiency, but also the 
ability to select infections of  tumor cells[63]. As a result, 
an amplification effect of  the therapeutic gene can be 
achieved through the lateral spread of  the progeny 
vector[63]. 
The latest generation of  adenoviral vector is the 
gutless adenovirus. It has become an attractive agent 
for gene therapy because of  the reduction of  in vivo 
immune response[64] and long-term sustained expression. 
However, because of  the lack of  all viral coding regions, 
the packaging of  this virus requires the presence of  helper 
virus which presents the possibility of  contamination[64]. 
Recombinant adeno-associated virus: Recombinant 
adeno-associated virus (rAAV) has the advantages of  
broad host range, low level of  immune response, and 
longevity of  gene expression that enable the initiation of  a 
number of  clinical trials using this gene delivery system[65]. 
As reviewed recently, there are 8 well-defined serotypes 
(serotypes 1-5 and 7-9), and more than 100 variants[66]. The 
underlying mechanism of  the selective tissue tropism of  
different serotypes remains elusive[66]. For anti-angiogenesis 
cancer gene therapy using rAAV, recent research examples 
are focusing on treating colon cancer (in vitro and in 
vivo), ovarian cancer (in vivo) and human glioblastoma (in 
vitro)[25,67,68].
TUMOR SPECIFICITY AND GENE DELI-
VERY: LESSONS FROM CLINICAL TRIALS
While previous studies on gene targets are limited to pre-
clinical stages, the recombinant proteins of  some of  these 
targets have entered clinical trials. Can we learn lessons 
from the trials to optimize the specificity and efficiency of  
the candidate gene therapeutics?
Recombinant endostatin is currently the most studied 
angiogenesis inhibitor in the clinical setting. The earliest 
phaseⅠtrials were published in 2002 and 2003[69-72]. 
However, the results were disappointing. Two very recent 
reports stated that although the endostatin trials have 
confirmed the safety of  endostatin as a pharmacological 
agent, it is difficult to establish the biologically effective 
dose of  the recombinant protein[73,74]. To address the 
problem of  effective dose of  endostatin, Tjin Tham Sjin 
et al[75] recently demonstrated that adeno-associated viruses 
carrying canine endostatin can dose-dependently express 
transgene in the circulation after intramuscular injection 
in mice. Elevated levels of  endostatin remain stable in the 
circulation for at least 4 mo[75]. Therefore, adeno-associated 
virus-mediated endostatin gene therapy appears to be a 
potential therapeutic regime with specific and sustained 
delivery efficiency.
IL-12 is another widely studied agent with anti-
angiogenesis activity in clinical trials. Recombinant human 
IL-12 protein has entered phaseⅠand Ⅱ studies in 
Germany and United States, respectively[3]. Due to the 
occurrence of  dose-limiting toxicity in some patients, 
the direction of  study has switched to gene therapy 
approaches[3]. A phaseⅠtrial involving an adenoviral 
vector encoding human IL-12 gene has been conducted[76], 
showing that dose-limited toxicity is significantly increased 
in tumor infiltration by effector immune cells. Despite the 
lower anti-tumor power of  IL-12 gene therapy in human 
trials, the concept of  stimulation of  immune response by 
specific production of  IL-12 inside a tumor is proved[77]. 
Recently, attention has been paid to combination 
therapy in which anti-angiogenesis treatment is combined 
with chemotherapy as well as radiotherapy[78]. Approaches 
like combination of  endostatin and VGFR-2 tyrosine 
kinase inhibitor and even tri-combination of  anti-
angiogenesis, chemotherapy and radiotherapy have also 
been tested[79,80]. Co-targeting of  tumor and tumor micro-
environment can effectively suppress angiogenesis and 
tumor growth in the prostate cancer model[81]. A Chinese 
phase Ⅲ trial using recombinant endostatin in combination 
with chemotherapy in NSCLC has exhibited a significant 
increase in response rates and time to progression[73].
Specificity and safety of  the vectors are the two main 
issues that should be addressed in the future. Development 
of  vectors that exhibit superior safety and direct the 
therapeutic transgene to the right target position of  the 
genome without any random insertion side effects would 
be a direction for studying human gene therapy against 
cancer.
CONCLUSION
Targeting angiogenesis is a promising approach in 
suppressing tumor growth and metastasis. Due to the 
need for long term administration of  the inhibitors, gene 
therapy has become an alternative which theoretically 
ensures a sustained availability of  the anti-angiogenesis 
agents. Up till now, researches on anti-angiogenesis 
cancer gene therapy remain in pre-clinical stage. It is 
anticipated that when better vectors are developed and the 
molecular mechanisms of  angiogenesis inhibitors against 
tumor growth are better understood, clinical trials will be 
undertaken in the future.
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